CClinicalTrials.gg
Status unknownNCT04011306Updated Jan 14, 2020

A Feasibility Study of a Novel Phototherapy System for the Management of Acute Burns

An interventional study of Lumina24 BLU in Burn Wound, sponsored by Rogers Sciences Inc.. Status unknown at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-14.

Sponsored by Rogers Sciences Inc. · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary purpose of this feasibility study is to evaluate safety and effectiveness in healing outcomes of patients treated with Lumina24TM BLU (treatment), a Continuous Low-Irradiance Phototherapy (CLIP) device, as compared to standard of care (SOC) therapy (control) for the treatment of acute burns.

Read the detailed description

This feasibility study will consist of up to 15 subjects (Cohort I: up to 10 subjects with partial thickness second-degree burns; Cohort II: up to 5 subjects with deep partial thickness second- and/or full thickness third-degree burns). Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site. If the subject has bilaterally symmetric burns, they will be randomized to receive SOC or Lumina24TM BLU at the distinct anatomical burn locations (e.g. right/left thigh, right/left shoulder, etc.). The proposed feasibility study will inform critical primary and secondary outcome measures and procedural improvements necessary for a pivotal clinical study that would demonstrate both antimicrobial effectiveness and improved wound healing of acute burn wounds.

02

Conditions studied

  • Burn Wound

Browse trials for

03

In context

Burns

719 studies on the registry are indexed under Burns; 145 are open to participants now.

This study's planned enrollment of 15 is below the median of 40 across 524 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

Rogers Sciences Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Males or females age > 18 to \< 65
  • BMI > 20 kg/m2
  • Patients anticipated to receive inpatient care for a minimum of 72 hours at the respective medical facility for partial thickness second-degree, deep partial thickness second-degree and/or full thickness third-degree burn wounds.
  • Patients who have a > 5% to \< 50% Total Body Surface Area (TBSA) wound.
  • Patients are willing and able to adhere to the therapy and protocol.
  • Female of childbearing potential must be willing to use acceptable methods of contraception.
  • Patients may or may not have clinical signs and symptoms of burn site infection at baseline.
  • Subject has read, understood and signed the approved ICF before screening procedures either by the patient or their legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • Subjects with burns > third-degree (i.e. involvement of deeper tissues, such as muscle, tendons, or bone)
  • Patients deemed not medically stable by the treating Investigator.
  • Patients with burn wounds limited to their head or genitalia.
  • Patients currently enrolled or participating in another investigational device, drug or biological trial that would interfere with the Lumina24TM application.
  • Patients with inhalation burns.
  • Patients who are clinically septic.
  • Patients are pregnant.
  • Patients on a ventilator, who are undergoing acute fluid resuscitation, are hemodynamically unstable or are deemed 'comfort measures only'.
  • In the opinion of treating physician, patient not expected to survive beyond 30 days.
  • Pregnant or lactating status. Pregnancy as determined by a positive pregnancy test at screening or baseline.
  • Known history of HIV infection, or active Hepatitis B or Hepatitis C infection.
  • Cancer requiring chemotherapy or radiation within previous 6 months or resection within the last 5 years (other than basal cell carcinoma.
  • Known chronic renal failure (serum creatine > 2 mg/dL) or chronic liver disease.
  • Pre-existing medical condition requiring current use of immunosuppressive medication or systemic steroids
  • Pre-existing medical conditions that would interfere with wound healing (i.e. diabetic patients with Hemoglobin A1c test result > 8%, malignancy, autoimmune disease)
  • Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance
  • Chronic illicit drug or alcohol abuse that is anticipated to interfere with patient compliance with the protocol
  • Subject is incarcerated at the time of screening.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Lumina24 BLU

    Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site.

    Device: Lumina24 BLU

Interventions

  • DeviceLumina24 BLU

    Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns

06

What researchers measure

Primary outcomes

  1. Wound Healing

    Percentage area reduction (PAR) of the acute burn wound (SOC control site vs. Lumina24TM BLU treatment site)

    Time frame: up to 28 days

  2. Number of adverse events

    Safety measured by incidence of product-related AEs, SAEs, and UADEs

    Time frame: up to 28 days

  3. Microbial load counts (Cohort II only)

    Difference of bioburden in/on the burn wound (SOC control site vs. Lumina24TM BLU treatment site) assessed by quantitative analysis of microbial load counts obtained from 3-mm punch biopsies and wound cultures

    Time frame: up to 28 days

Secondary outcomes

  1. Time to healing

    Time to burn wound healing at end of inpatient treatment

    Time frame: 12 months

  2. Numerical Pain Rating Scale

    Difference in pain related to acute burn wounds between SOC control site and Lumina24TM BLU treatment site assessed by patient-reported rating ranging from 0 to 10 (where 0 represents no pain and 10 represents worst possible pain)

    Time frame: 12 months

  3. Cost-effectiveness

    Difference in cost-effectiveness of treatment regime between Lumina24TM BLU and SOC control assessed by difference in sum of costs associated with each treatment regime (including costs of OR visits required, inpatient stay, grafts and/or biologics used)

    Time frame: 12 months

  4. Patient and Observer Scar Assessment Scale

    Difference in healing of hypertrophic scarring between SOC control site and Lumina24TM BLU treatment site assessed by Patient and Observer Scar Assessment Scale

    Time frame: 12 months

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04011306
Lead sponsor
Rogers Sciences Inc.
Responsible party
Sponsor
First posted
Jul 8, 2019
Start date
Feb 2020 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Aug 2021 (estimated)
Last update
Jan 14, 2020

Study contacts

David W. Mozingo, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion